Alzheimer's disease drug shows early promise



New Alzheimer’s Drug Shows Promise in Trial

Experimental drug called BAN2401 slowed disease progression by targeting amyloid plaques.

By Becky Upham

Don't Miss This

Sign Up for OurHealthy LivingNewsletter

Thanks for signing up!You might also like these other newsletters:

A computer illustration shows amyloid plaques (pictured in yellow), which can damage brain neurons in Alzheimer’s patients.
A computer illustration shows amyloid plaques (pictured in yellow), which can damage brain neurons in Alzheimer’s patients.
Juan Gaertner/Alamy

July 26, 2019

There is renewed hope in the battle to fight Alzheimer’s disease, thanks to an experimental new drug. Results from a phase 2 clinical trial show that the medication, an antibody called BAN2401, slowed the progression of the disease and increased cognitive performance.

Drugmakers Biogen and Eisai presented details about the clinical trial yesterday, July 25, 2019, at the Alzheimer’s Association International Conference in Chicago.

The trial involved 856 patients with mild cognitive impairment related to Alzheimer’s, who were divided into six groups. Five groups of patients were given various doses of the drug, and one group was given a placebo. The study assessed changes over 18 months by looking at levels of amyloid in the brain. Alzheimer’s patients have abnormal levels of the amyloid proteins that can clump together to form plaques. These plaques collect between neurons and disrupt cell function, according to the National Institute on Aging.

The study also used three common cognitive assessments for Alzheimer’s and dementia to determine changes in brain functioning.

At its highest dose, the drug reduced amyloid proteins as much as 93 percent. The trial also reported a 26 to 30 percent improvement in cognition.

Amyloids and Alzheimer’s

“This is the first late-stage anti-amyloid antibody study to successfully achieve statistically significant results at 18 months, further validating the amyloid hypothesis,” said Lynn Kramer, MD, chief clinical officer and chief medical officer of Eisai’s neurology business group.

“Overall, these findings are very exciting,” says Daniel Kaufer, MD, director of the memory disorders program at the University of North Carolina in Chapel Hill. “In this population, the treatment was able to reduce amyloids in people’s brains, and that that was correlated with clinical improvement in slowing people’s decline over 12 to 18 months.” he says.

Dr. Kaufer emphasizes that the clinically significant effects of the treatment correlated with the dose. “The higher the dose of treatment, the greater reduction in amyloid and the greater the clinical effect,” he says. “When you’re evaluating any treatment, that association is a very reassuring sign.”

Kaufer points out that one aspect of the trial’s design makes its findings a little more difficult to compare to a conventional study design. Rather than randomly distribute patients into six groups, the researchers used something called a Bayesian adaptive randomization design. “That means that as they enrolled new subjects in the study, they first looked at preliminary outcomes. They used that information to modify how they enrolled future subjects in the study,” says Kaufer. He adds that the approach makes it harder to speculate how these findings will translate into a real-world clinical practice.

Cautious Optimism

But Kaufer is cautiously optimistic, and he expects that a phase 3 trial will provide answers to lingering questions. “Is it going to work? Is it going to be safe?” he asks. “Until those results, you really can’t say anything definitive about the treatment,” he adds.

The conclusion of that trial, as well as any potential approval by the Food and Drug Administration, are still two or more years away. “Part of the problem is that these studies take a long time,” Kaufer says. “The outcomes in this study were evaluated at 12 to 18 months.






Video: Alzheimer's disease drug fails in trial

New Alzheimer’s Drug Shows Promise in Trial
New Alzheimer’s Drug Shows Promise in Trial images

2019 year
2019 year - New Alzheimer’s Drug Shows Promise in Trial pictures

New Alzheimer’s Drug Shows Promise in Trial recommendations
New Alzheimer’s Drug Shows Promise in Trial recommend photo

New Alzheimer’s Drug Shows Promise in Trial pics
New Alzheimer’s Drug Shows Promise in Trial picture

New Alzheimer’s Drug Shows Promise in Trial New Alzheimer’s Drug Shows Promise in Trial new pictures
New Alzheimer’s Drug Shows Promise in Trial new foto

photo New Alzheimer’s Drug Shows Promise in Trial
pics New Alzheimer’s Drug Shows Promise in Trial

Watch New Alzheimer’s Drug Shows Promise in Trial video
Watch New Alzheimer’s Drug Shows Promise in Trial video

Forum on this topic: New Alzheimer’s Drug Shows Promise in Trial, new-alzheimers-drug-shows-promise-in-trial/
Communication on this topic: New Alzheimer’s Drug Shows Promise in Trial, new-alzheimers-drug-shows-promise-in-trial/ , new-alzheimers-drug-shows-promise-in-trial/

Related News


More Dentists and Pharmacists, More Opioid Rx Abuse
How to Use Hypnosis to Overcome Challenges in Your Life
Beyoncé: the Obamas are my inspiration
Studies reveal mens sperm count has plunged over the last 40 years
The Queen just surprised a four-year-old boy on his birthday
5 Make-Ahead Breakfasts for Weight Loss
How to Enjoy Writing a Diary
1. Waverley — The UKs most prosperous area, according to the Legatum Institute, is in Surrey. The region is home to the town of Godalming, and is well known for its green space. Its best single sub-index score was for health, where it finished 8th
Who’s on the front row at London Fashion Week
How to Sing With a Cold
How to Maintain a Friendship After a Kiss
How to Record Your Desktop to Video Using TotalScreenRecorder
How to Throw a Christmas Party on a Budget
American Idol Results Tonight



Date: 06.12.2018, 23:40 / Views: 94295